Research and Markets: ADHD Pharmaceuticals to Branch Out

Fri Jun 7, 2013 4:14am EDT

* Reuters is not responsible for the content in this press release.

Research and Markets: ADHD Pharmaceuticals to Branch Out

Research and Markets (http://www.researchandmarkets.com/research/2p44zm/adhd_therapeutics) has announced the addition of the "ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment" report to their offering.

While high disease prevalence encourages pharmaceutical companies to enter into the ADHD market, a lack of understanding surrounding the condition makes drug development problematic, states GBI Research.

A new report* states that, as multiple ADHD drugs such as Adderall XR (amphetamine and dextroamphetamine), Daytrana (methylphenidate), Intuniv, Concerta (methylphenidate), Strattera (atomoxetine) and Kapvay are set to lose their patents, new treatment options are required to prevent declining market revenue. However, uncertain disease epidemiology is making development difficult.

The ADHD pipeline features some promising molecules, but many are still in early stages of development. The pathophysiology of ADHD is not well understood, as scientific research has struggled to provide any definitive genetic neurological, psychological or environmental causes. The overlap between the mechanisms of action found in different phases of the pipeline could be due to multiple pharma companies chasing the same recent discoveries, and until the disease mechanism has been established, this competition seems likely to continue.

Treatments which lack the significant side effects of existing treatments would do very well in the ADHD market. All existing therapeutics hold a range of significant negative side effects, including fatigue, nausea, weight loss, insomnia, and even tics. Stimulant therapeutics also hold the potential for abuse, performance enhancement and even recreational purposes, leading to their classification as Schedule II controlled substances in the US and as controlled narcotics in Japan. Adderall and Strattera even carry black box warnings from the FDA due to the risks associated with their use.

The approval of ADHD drugs across various regional markets could help the therapeutics market. Certain medications are already approved in the US, but not in Europe and Japan, and their use across all geographic regions could greatly improve their revenues. Vyvanse (lisdexamfetamine dimesylate) is a longer lasting, harder to abuse form of dextroamphetamine, which is the active ingredient in Adderall, and its launch in major European markets in early 2013 is expected to lead to wide adoption across the continent, buoying the region's ADHD therapeutics market.

Drug repositioning also examines the best way to use existing products. Approved pharmaceuticals already have valuable clinical data on toxicity, safety, and dosing, reducing the time, risk and costs involved in drug development, and various products already marketed for other indications are currently being considered for ADHD, including medications for vertigo, alcohol withdrawal, and other CNS disorders. In the current economic climate, payers will often opt for the cheapest therapeutic option rather than the most efficient therapeutic, and so companies could benefit handsomely by attributing pre-existing and modestly priced medications to treat ADHD.

This report provides insights into the up-and-coming trends of the ADHD market in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan. The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals.

Products Mentioned

- Adderall XR (mixed amphetamine salt)

- Concerta (methylphenidate hydrochloride)

- Daytrana (methylphenidate transdermal patch)

- Focalin XR (dexmethylphenidate hydrochloride)

- Intuniv (guanfacine)

- Kapvay (clonidine hydrochloride)

- Strattera (atomoxetine hydrochloride)

- Vyvanse (lisdexamfetamine dimesylate)

For more information visit http://www.researchandmarkets.com/research/2p44zm/adhd_therapeutics

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals, Diagnostics

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.